PURPOSE: To assess the frequency with which editorial authors report personal conflict of interest and investigate a possible association between the presence of such conflicts and favorable opinion. METHODS: Eligible studies were editorials of phase III clinical trials of antitumor drugs or symptom management published from January 2007 to December 2009 in four top oncology journals. Data from the editorials were collected and each editorial opinion was classified as favorable, neutral or unfavorable with respect to the experimental therapy. RESULTS: Fifty-four editorials were included: 23 (43%) reported at least one conflict of interest, with the most frequent one being consultancy fees. Conclusions of editorial authors were classified as favorable in 18 editorials (33%). Sensitivity analysis found an association between self-reported conflict of interest of the editorial author and editorial favorable opinion (RR:2.7; 95% CI 1.2-6.1; p=0.019). DISCUSSION: Besides the high proportion of conflict of interest among editorial authors discussing phase III clinical trials, study interpretation may be influenced by their financial relationships with industry.
PURPOSE: To assess the frequency with which editorial authors report personal conflict of interest and investigate a possible association between the presence of such conflicts and favorable opinion. METHODS: Eligible studies were editorials of phase III clinical trials of antitumor drugs or symptom management published from January 2007 to December 2009 in four top oncology journals. Data from the editorials were collected and each editorial opinion was classified as favorable, neutral or unfavorable with respect to the experimental therapy. RESULTS: Fifty-four editorials were included: 23 (43%) reported at least one conflict of interest, with the most frequent one being consultancy fees. Conclusions of editorial authors were classified as favorable in 18 editorials (33%). Sensitivity analysis found an association between self-reported conflict of interest of the editorial author and editorial favorable opinion (RR:2.7; 95% CI 1.2-6.1; p=0.019). DISCUSSION: Besides the high proportion of conflict of interest among editorial authors discussing phase III clinical trials, study interpretation may be influenced by their financial relationships with industry.
Authors: Aaron N Winn; Aaron P Mitchell; Nicole Fergestrom; Joan M Neuner; Justin G Trogdon Journal: J Gen Intern Med Date: 2021-04-26 Impact factor: 6.473
Authors: Camilla Hansen Nejstgaard; Lisa Bero; Asbjørn Hróbjartsson; Anders W Jørgensen; Karsten Juhl Jørgensen; Mary Le; Andreas Lundh Journal: Cochrane Database Syst Rev Date: 2020-12-08
Authors: Camilla H Nejstgaard; Lisa Bero; Asbjørn Hróbjartsson; Anders W Jørgensen; Karsten J Jørgensen; Mary Le; Andreas Lundh Journal: BMJ Date: 2020-12-09
Authors: Alice Fabbri; Camilla Hansen Nejstgaard; Quinn Grundy; Lisa Bero; Adam G Dunn; Annim Mohammad; Barbara Mintzes Journal: J Gen Intern Med Date: 2021-05-26 Impact factor: 5.128